Triple-negative breast cancer (TNBC) has long been one of the most challenging cancer types to treat because it lacks hormone and HER2 receptors that most targeted drugs act upon. But recent clinical data has brought a real sense of progress.
AstraZeneca and Daiichi Sankyo’s new drug, Datroway, showed a 23% improvement in overall survival and a 43% increase in progression-free survival compared to standard chemotherapy. Gilead’s Trodelvy and Lilly’s Verzenio also demonstrated meaningful survival benefits for patients who previously had limited treatment options.
These results signal a genuine shift in how we approach TNBC therapy, showing that innovation in targeted treatments can finally begin to change outcomes in this aggressive cancer type.
Do you think these new targeted therapies could eventually make chemotherapy a secondary option in aggressive cancers like TNBC?
MBH/AB